LH · News · 20260809N
Product Launch and Transition
LABCORP HOLDINGS INC. · 2026-08-09 · Importance 34 · Surprise 42 · In source text
Labcorp announced nationwide availability of Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay. The prostate-cancer diagnostic supports precision oncology and personalized cancer-care applications. The launch strengthens Labcorp's positioning in oncology testing, although third-party reporting noted reimbursement pressure and competitive pricing as risks.
Key facts
- Labcorp announced nationwide availability of Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay. source
- Labcorp is expanding its consumer offerings like ColoSense and Labcorp OnDemand. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Labcorp announced nationwide availability of Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay. |